Indian states suspend off-label Avastin use after side effects; Merck KGaA adds two to its executive board;

@FiercePharma: New strain of avian flu confirmed in Indiana poultry flocks. FierceAnimalHealth item | Follow @FiercePharma

@EricPFierce: FDA says this Hong Kong plant pretty much had not quality control in place. FiercePharmaManfacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: PTO shuts down Amgen's Humira IP challenge. Article | Follow @CarlyHFierce

> Two Indian states halted off-label use of Roche's ($RHHBY) Avastin for vision conditions after more than a dozen patients underwent surgery for pain and swelling in their eyes. Report

> The Danish enzyme maker Novozymes separated its biopharma activities into an independent company called Albumedix. Report

> Merck KGaA tapped two new members for its executive board, Udit Batra, who heads up its life science business recently enlarged with its Sigma-Aldrich buyout; and Walter Galinat, who heads up performance materials. Release

> Aurobindo Pharma won FDA approval for its version of the Pfizer ($PFE) clotting drug Cyklokapron (tranexamic acid). Report

Medical Device News

@FierceMedDev: Second activist investor buys 5% stake in HeartWare, putting Valtech deal in doubt. Article | Follow @FierceMedDev

@VarunSaxena2: Interesting article in . Which lifesci hub do you think is no. 1? More (reg. req.) | Follow @VarunSaxena2

@EmilyWFierce: Shkreli, Valeant CEO set for a grilling at Congressional price-hike hearing. FiercePharma story | Follow @EmilyWFierce

> Startup raises $19M to market suture-replacing, Zip skin closure products. Report

> J&J axes 3,000 jobs in bid to save $1B and revive lagging medical devices business. Article

Biotech News

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: And in case you missed it: Eleven Bio faces cash crunch as lead drug flunks another PhIII. Article | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. More | Follow @DamianFierce

> Samsung and Biogen win first EU approval for an Enbrel copycat. Report

> French drug trial disaster leaves patient dead amid a slew of unanswered questions. Story

> Acorda bags PhIII Parkinson's drug in $363M Biotie buyout. Article

Animal Health News

> New strain of avian flu confirmed in Indiana poultry flocks. Story

> Affymetrix teams with Bio-Genesys to offer genetic testing for livestock. More

> Animal drugs, diagnostics and distribution on display at J.P. Morgan confab. Item

> EMA launches review of 'last-resort' antibiotic after scientists ID resistance gene. Report

> Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. Article

Biotech IT News

> BioMed X emerges from Merck KGaA alliance armed with bioinformatics tools. News

> NIH kicks off $313M genome sequencing drive. Report

> Illumina moves into semiconductor-based sequencing with Project Firefly. More

> Biden puts data sharing at center of drive to cure cancer. Article

> Astellas hooks up with NuMedii to continue drug repurposing deal drive. Story

Drug Delivery News

> Dental anesthesia delivered via electric current could offer needle-free alternative. Item

> Will FDA panel's second recommendation of approval for implant to treat opioid addiction be enough? More

> Takeda teams up with enGene for gastrointestinal gene delivery R&D. Report

> Catalent to earn up to $618M under antibody-drug conjugate research alliance with Roche. Story

> Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors. Article

Pharma Manufacturing News

> Mylan halts production at Poland plant after inspectors uncover problems. News

> Plant-based biologics production to be offered by new CMO. Item

> FDA slams another Chinese drugmaker with a warning letter. Story

> Emcure, which has issues with FDA, buys Canadian firms. Report

> Wockhardt's new sterile injectable plant issued a Form 483 by the FDA. Article

Pharma Asia News

> Unit of Singapore's Biosensors refuses U.S. FDA inspection. Item

> Redesigned scope by Japan's Olympus cleared by FDA. More

> Japanese drugmakers shift focus as government pushes for more generics. Report

> Sanofi may get waiver from large-scale dengue vaccine trials in India. Story

> Healthcare reform in China raises tensions between hospitals, pharma companies. Article

And Finally... Oncologists complain that there are too many conflicting treatment pathways, some of them developed by payers for self-serving reasons. Report

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.